Research programme: respiratory disorders therapeutics - Protalix Biotherapeutics
Alternative Names: PRX-107Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Protalix Biotherapeutics
- Developer Protalix BioTherapeutics
- Class Recombinant proteins
- Mechanism of Action Alpha 1-antitrypsin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Emphysema
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Emphysema in Israel (Inhalation)
- 20 Jun 2013 Preclinical development is ongoing in Israel
- 31 Dec 2009 Preclinical in Emphysema in Israel (Inhalation)